Recent Trends in In Situ Enzyme-Activatable Prodrugs for Targeted Cancer Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, In-Cheol | - |
dc.contributor.author | Yoon, Hong Yeol | - |
dc.contributor.author | Lim, Dong-Kwon | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.date.accessioned | 2021-08-31T04:43:54Z | - |
dc.date.available | 2021-08-31T04:43:54Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 1043-1802 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/56744 | - |
dc.description.abstract | Enzyme-activatable anticancer prodrugs are modified medications that are composed of an anticancer drug, cleavable linker, and functional moiety. The purpose of such a prodrug structure is to generate multipurpose functions that traditional drugs cannot perform and to reduce the toxicity of conventional anticancer drugs by the mask of the cleavable linker. Once the cleavable linker is degraded via a specific chemical reaction in the cancer microenvironment, the cytotoxicity of the degraded prodrugs is selectively recovered. Among many factors that cleave the linker, we focus on the overexpressed enzymes in cancer. Because of the selective enzymatic degradation of the cleavable linker and the high local concentration of specific enzymes in cancer, the enzyme-activatable prodrugs could show low toxicity in normal tissues, while showing comparable anticancer effect in tumors. In addition, some prodrugs provide additional features, such as cancer imaging, drug release monitoring, tumor targeting, and enhanced stability, which conventional anticancer drugs cannot possess. In this review, we summarize currently developed enzyme-activatable prodrugs according to their activating enzymes, and categorize them by their additional functions, e.g. targeting, imaging, and delivery. This summary of enzyme-activatable prodrugs may help in the design of anticancer prodrugs, and in the establishment of a personalized cancer treatment strategy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | MATRIX METALLOPROTEINASES | - |
dc.subject | HUMAN CARBOXYLESTERASES | - |
dc.subject | DT-DIAPHORASE | - |
dc.subject | THERANOSTIC NANOPARTICLES | - |
dc.subject | HISTONE DEACETYLASES | - |
dc.subject | TUMOR HETEROGENEITY | - |
dc.subject | PACLITAXEL PRODRUG | - |
dc.subject | CONTROLLED-RELEASE | - |
dc.subject | AMINOPEPTIDASE-N | - |
dc.title | Recent Trends in In Situ Enzyme-Activatable Prodrugs for Targeted Cancer Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Dong-Kwon | - |
dc.contributor.affiliatedAuthor | Kim, Kwangmeyung | - |
dc.identifier.doi | 10.1021/acs.bioconjchem.0c00082 | - |
dc.identifier.scopusid | 2-s2.0-85083545863 | - |
dc.identifier.wosid | 000526391900013 | - |
dc.identifier.bibliographicCitation | BIOCONJUGATE CHEMISTRY, v.31, no.4, pp.1012 - 1024 | - |
dc.relation.isPartOf | BIOCONJUGATE CHEMISTRY | - |
dc.citation.title | BIOCONJUGATE CHEMISTRY | - |
dc.citation.volume | 31 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1012 | - |
dc.citation.endPage | 1024 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASES | - |
dc.subject.keywordPlus | HUMAN CARBOXYLESTERASES | - |
dc.subject.keywordPlus | DT-DIAPHORASE | - |
dc.subject.keywordPlus | THERANOSTIC NANOPARTICLES | - |
dc.subject.keywordPlus | HISTONE DEACETYLASES | - |
dc.subject.keywordPlus | TUMOR HETEROGENEITY | - |
dc.subject.keywordPlus | PACLITAXEL PRODRUG | - |
dc.subject.keywordPlus | CONTROLLED-RELEASE | - |
dc.subject.keywordPlus | AMINOPEPTIDASE-N | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.